Dr Reddy's Laboratories, Global Response Aid,
and Appili Therapeutics announced the filing of an application for REEQONUS (favipiravir) Tablets
News Desk, News Nation 360 : Dr Reddy’s Laboratories Ltd., (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr Reddy’s”), Appili Therapeutics (TSX: APLI; OTCQX: APLIF), and Global Response Aid FZCO (GRA) today announced that Dr Reddy’s Canada has filed an application on behalf of the consortium for REEQONUS™ (favipiravir) Tablets for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. REEQONUS™ is also known as Avigan® (favipiravir) Tablets developed by FUJIFILM Toyama Chemical Co., Ltd. In September, the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 was signed by the Minister of Health in Canada to create a new authorization pathway that will help expedite the authorization of drugs and vaccines for COVID-19. According to Health Canada, REEQONUS™ (favipiravir) Tablets are the first oral solid dosage form submitted under the Interim Order. Vinod Ramachandran PhD, Vice President and General Manager, Dr Reddy’s Laboratories Canada Inc said that they are pleased to work with their partners at GRA and Appili to be the first in Canada to file an application for oral solid tablets for COVID-19 treatment under Health Canada’s Interim Order, Dr Reddy’s is working closely with Health Canada for an expedited review of the drug application, as speed to market is essential in these unprecedented times. If approved, they look forward to launching this important product soon to benefit the lives and health of COVID-19 patients in Canada.
Report : Anustup Kundu